All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Published:2019-01 Issue: Volume:106 Page:89-98
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Dimopoulos Meletios A.,Grosicki Sebastian,Jędrzejczak Wiesław W.,Nahi Hareth,Gruber Astrid,Hansson Markus,Gupta Neeraj,Byrne Catriona,Labotka Richard,Teng Zhaoyang,Yang Huyuan,Grzasko Norbert,Kumar Shaji

Funder

Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN);Palumbo;Blood,2011

2. EHA SWG on ‘Aging and Hematology’. Elderly patients with multiple myeloma: towards a frailty approach?;Zweegman;Curr Opin Oncol,2017

3. Continuous lenalidomide treatment for newly diagnosed multiple myeloma;Palumbo;N Engl J Med,2012

4. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival;Palumbo;J Clin Oncol,2014

5. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma;Palumbo;J Clin Oncol,2015

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

2. In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts;Experimental Hematology;2024-04

3. Therapeutic Effect and Adverse Event Rate of Different Treatment Methods in Patients with Multiple Myeloma and Renal Insufficiency;International Archives of Allergy and Immunology;2024

4. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12

5. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07